A new scare campaign against peptides follows a familiar pattern: use a few cases of contamination to justify sweeping restrictions on natural therapies that compete with pharmaceutical drugs.
Listen to the audio version of this article:
THE TOPLINE
- A recent peptide study found contamination and purity problems in some “gray market” products—but contamination is already illegal, and the FDA already has authority to target bad actors.
- This mirrors the FDA’s approach to homeopathy and supplements, where isolated violations are used to portray entire categories as unsafe.
- The real battle is over access: as peptides gain attention for regenerative medicine, metabolic health, and healthy aging, regulators are moving toward tighter controls that favor patented pharmaceutical products over naturally derived therapies.
A new preprint study on “research-grade” peptides is already being used to reinforce a familiar narrative: natural or naturally-derived therapies are too risky for consumers and therefore require tighter FDA control. Sound familiar? We’ve seen the same playbook used against homeopathy, supplements, and compounded medicines for years.
The real danger is not peptides themselves. In fact—quite the opposite—peptides are among the most important signaling molecules (including hormones) in the body and deficiencies or imbalances in them are major reason for metabolic, hormonal, neurological and immunological dysregulation that leads to an array of different diseases and premature aging. It’s the growing effort to use isolated examples of contamination and bad manufacturing practices to justify restricting entire categories of therapeutic products that compete with pharmaceutical drugs. We think it’s no coincidence that hit-pieces against peptides are popping up just as RFK Jr. has recently signaled that he will take action to ensure consumer access to several important peptides.
The preprint analyzed more than 6,000 peptide samples from the so-called “gray market.” The authors found that many products did not meet purity benchmarks and that some contained endotoxin contamination.
Those findings should concern everyone. No one wants contaminated injectable products on the market. But contamination and adulteration are already illegal. The FDA does not need sweeping new authority to police unsafe manufacturing. Existing laws already prohibit contaminated, adulterated, or misbranded products. We’ve argued previously that FDA policy has had a hand in creating this gray market: when regulators restrict access to substances that patients and clinicians believe are beneficial, those substances don’t disappear—they’re pushed into the shadows where unscrupulous actors thrive.
The problem is enforcement against bad actors—not the existence of peptides themselves.
The Same Strategy Used Against Homeopathy
This is precisely the argument ANH-USA has made in its legal fight against the FDA’s crackdown on homeopathic medicines.
In court filings challenging the FDA’s anti-homeopathy campaign, we argued that the agency relied on isolated and unrepresentative instances of manufacturing violations to paint an entire category of products as unsafe.
As we explained, that’s like shutting down every restaurant in America because a few of them failed hygiene inspections.
You see how the same principle gets re-used in the FDA’s playbook—whether it involves peptides, homeopathics, or dietary supplements?
A contaminated peptide product is not evidence that all peptides are unsafe any more than a contaminated supplement proves all supplements are dangerous or a poorly manufactured homeopathic medicine invalidates homeopathy altogether.
Properly manufactured products made under Good Manufacturing Practices (GMPs) can be produced safely. The FDA already has authority to enforce GMP violations, seize contaminated products, and prosecute fraudulent manufacturers.
Instead, the agency repeatedly uses safety scares to justify broader restrictions on entire categories of natural health products.
Peptides Represent a Threat to the Drug Monopoly
Peptides are attracting enormous interest because they sit at the frontier of regenerative medicine, metabolic health, injury recovery, immune modulation, and healthy aging. Many are naturally occurring signaling molecules composed of amino acids—the same building blocks that make up proteins in the human body.
Research into compounds like BPC-157, thymosin alpha-1, kisspeptin-10, and epitalon has generated excitement because of their potential therapeutic applications. That promise also creates a commercial problem for the pharmaceutical industry.
Natural or bioidentical compounds are difficult to monopolize. As ANH-USA has long argued, the FDA approval system strongly favors patent-protected pharmaceutical products because only monopoly pricing can justify the enormous costs of FDA drug approval.
When naturally-occurring substances begin competing with patented drugs, regulators suddenly discover “safety concerns.”
We saw it with supplements. We saw it with homeopathy. We are now seeing it with peptides.
In 2023, ANH-USA warned that the FDA was moving to prohibit the compounding of multiple peptides by citing concerns over impurities and insufficient safety data. The agency placed numerous peptides into “Category 2,” meaning compounders could no longer continue producing them while FDA review was underway.
The justification? Potential contamination risks and theoretical safety concerns.
A Pattern of Regulatory Overreach
ANH-USA has documented this pattern repeatedly across natural health.
With supplements, the FDA has attempted to impose drug-style premarket requirements that threaten innovation and consumer access.
With homeopathy, the FDA abruptly abandoned decades of regulatory recognition of the category’s safety profile by pointing to isolated enforcement cases.
With peptides, the agency is again emphasizing contamination and impurity concerns while moving toward tighter restrictions that would conveniently leave pharmaceutical manufacturers holding the keys to access.
Meanwhile, properly manufactured compounded peptides and natural peptide therapies risk disappearing from the market entirely.
If the agency truly wants to protect public health, it should focus on enforcing existing manufacturing standards against bad actors while preserving access to properly manufactured peptide therapies. Otherwise, peptides may become the latest casualty in a long-running campaign against natural and naturally-derived health products—a campaign that consistently benefits pharmaceutical monopolies while restricting consumer choice.
Please share this article widely in your networks and consider donating to support our work.
